<DOC>
	<DOCNO>NCT01973569</DOCNO>
	<brief_summary>To evaluate inhibitory effect progression , compare placebo , joint destruction AMG 162 administer subcutaneously rheumatoid arthritis patient</brief_summary>
	<brief_title>AMG 162 ( Denosumab ) Phase 3 Study ( DESIRABLE Study ) Patients With Rheumatoid Arthritis Disease-modifying Antirheumatic Drugs ( DMARDs ) Treatment</brief_title>
	<detailed_description>To evaluate inhibitory effect progression , compare placebo , joint destruction AMG 162 administer subcutaneously dose 60 mg every 6 month every 3 month 12 month rheumatoid arthritis patient</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Diagnosed rheumatoid arthritis accord American College Rheumatology ( ACR ) criteria rheumatoid arthritis classification ( 1987 revision ) 2010 ACREULAR ( The European League Against Rheumatism ) classification criterion rheumatoid arthritis Functional class IV accord ACR revise classification ( 1991 )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Denosumab</keyword>
	<keyword>RANKL</keyword>
	<keyword>RANK</keyword>
	<keyword>AMG 162</keyword>
	<keyword>joint damage</keyword>
</DOC>